Business
ANI Pharmaceuticals Announces Launch of Nebivolol Tablets
-- Current annual market for reference listed drug (“RLD”) Bystolic® totals more than $1 billion -- -- Simultaneous launch from two manufacturing sites --
About this update from Ani Pharmaceuticals, Inc.
[{"type":"text","content":"\n-- Current annual market for reference listed drug (“RLD”) Bystolic® totals more than $1 billion --\n\n-- Simultaneous launch from two manufacturing sites --\n\n BAUDETTE, Minn.--(BUSINESS WIRE)--\nANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced the launch of Nebivolol Tablets, 2.5 mg, 5 mg, 10 mg, and 20 mg.\n\nANI’s Nebivolol Tablets is the generic version of the reference listed drug (“RLD”) Bystolic®. The current annual U.S. market for Bystolic 2.5 mg, 5 mg, 10 mg, and 20 mg strengths is approximately $1.05 billion, according to IQVIA/IMS Health, a leading healthcare data and analytics provider.\n\n\"The launch of Nebivolol Tablets highlights our research and development capabilities. On day one, we simultaneously launched across two manufacturing sites, including our site in Baudette, Minnesota, thus showcasing our ability to secure the supply chain for patients and customers,” stated Nikhil Lalwani, President and CEO of ANI Pharmaceuticals, Inc.\n\nAbout Nebivolol Tablets \n\nNebivolol Tablets are indicated for the treatment of hypertension, to lower blood pressure and may be used alone or in combination with other antihypertensive agents. For more information, including the complete list of indications and usages, please see the Full Prescribing Information.\n\nAbout ANI\n\nANI Pharmaceuticals, Inc. is a diversified bio-pharmaceutical company serving patients in need by developing, manufacturing, and marketing high quality branded and generic prescription pharmaceutical products. Our team is focused on delivering sustainable growth by building a successful Purified Cortrophin Gel® franchise, strengthening our generics business with enhanced development capability, innovation in established brands and leveraging our North American manufacturing capabilities. For more information, please visit our website www.anipharmaceuticals.com.\n\nForward-Looking Statements\n\nTo the extent any statements made in this release deal with information that is not historical, these are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, those relating to the development, manufacturing and commercialization of the product and any additional product launches from the Company’s generic pipeline, other statemen...